Anthropic IPO control: seven co-founders seek 50.1% of the vote with about 14% of the economics

Anthropic's seven co-founders are asking shareholders to approve a special class of shares that would give them a combined 50.1 percent of the vote on most corporate matters once the company is public. TechCrunch reported the plan on September 25, 2026, and Resultsense later described the structure from Anthropic's filing. Each founder owns roughly 2 percent of the company, so the group's economic stake is about 14 percent while its voting stake would be a majority.

If you are asking what Anthropic's IPO means for who controls a lab that says it is building the most powerful technology in history, this structure is the answer, and it is the part of the filing most worth reading.

What the structure is

Per TechCrunch, the new founder shares are "special shares carrying a combined 50.1% of the vote on most corporate matters," provided at least three founders keep minimum stakes. The shares "carry no extra economic value, but they'd preserve the group's control once the company starts trading publicly." Startup Fortune adds that voting control persists as long as at least three founders hold their stakes.

A second account, from Resultsense, describes the vehicle as a "Founder LLC" holding a Class F share worth 50.1 percent of votes on major decisions, so the founders act by majority inside the LLC. The same account says the company issues five share classes in all, and that the founders' control provisions phase out if fewer than two founders remain or after certain departures or sales. We could not open the filing directly this run, so treat the share-class details as reported, not confirmed from the document.

Three counterweights sit alongside it. The Long-Term Benefit Trust, an independent body set up in 2023, keeps its power to pick most of the board. Founder board seats would rise from two to three. And employees would get their own class of stock to break ties on certain issues.

Why the Trust matters more than the founders' vote

Anthropic's own description of the Trust is the benchmark. Its September 19, 2023 post says the Trust holds special Class T stock, and that "the Class T stock grants the Trust the authority to elect and remove a number of Anthropic's board members that will phase in according to time- and funding-based milestones; in any event, the Trust will elect a majority of the board within 4 years."

That is the safeguard the company pointed to when it argued a safety-minded lab could be accountable to something other than quarterly returns. According to Resultsense's reading of the filing, the Trust, which includes former Federal Reserve chair Ben Bernanke, would select four directors, while the Amodei siblings and a third director face election with Class F and Class A holders both voting. Daniela Amodei is president and board chair.

The question is which of the two powers is bigger. The Trust picks directors. The founders' 50.1 percent vote decides "most corporate matters." If a founder-controlled vote and a Trust-appointed board disagree on, say, whether to release a model, which one prevails? Nothing we opened answers that, and it is the question the structure turns on.

The risk language

The filing, as quoted by Resultsense, warns that the arrangement "may produce decisions that hurt the value of our Class A common stock" because Anthropic is a Delaware public benefit corporation that weighs humanitarian interests alongside shareholder returns. That is an unusual sentence to put in an offering document, and it is the honest one. Public investors would be buying economic exposure to a company whose controllers can overrule them. As Startup Fortune put it, they would get "economic exposure to one of the most valuable private companies on earth, and almost no say in how it's run."

The figures behind that are large. Startup Fortune says Anthropic was valued at $1.5 trillion on secondary markets, with potential IPO valuations reaching $2 trillion, and an annualized revenue run rate above $65 billion by July 2026. TechCrunch reports a $965 billion valuation in May 2026. Those are reported figures and estimates, not audited numbers. Anthropic has not confirmed a listing date in the coverage we opened, and this piece does not predict one.

The founders have also pledged to give away 80 percent of their wealth, and TechCrunch notes the structure resembles those used by Zuckerberg at Meta and Spiegel at Snap, though a group arrangement is unusual.

Why this is a race story

Control of a frontier lab is control over a decision the rest of us care about: when to stop. Dario Amodei's essay "We Must Pace the Frontier" asks the whole industry to slow capability progress when safety work lags. On September 23 he told the UN Security Council that AI could be "a risk to humanity as a whole." A listed company with outside shareholders, a Trust and a founder bloc is the entity that would have to carry out such a slowdown. Whether it can do so against a quarterly investor revolt depends exactly on the structure above.

There is a fair case for the founders' side. If the alternative is a lab where a majority of shareholders can force a faster release, voting control in the hands of people who have written essays about pacing is the safer default. Public benefit status helps too. That argument is credible, and it also relies on trusting the founders' judgment, which is a different thing from the institutional constraint the Trust was sold as in 2023.

Hype check

Anthropic's positioning is that its structure puts safety above profit. The filing evidence supports a split: the Trust keeps real board power, and founders gain majority voting control without a larger economic stake. Both exist on paper. How they interact is untested. We rate it mixed.

Our take

This is a governance fact, not a scandal. Founder control is common, and the Trust is a real feature. But the 50.1 percent vote narrows what the Trust can do, and public investors are being asked to accept that. What we would watch is the filing's conflict language, any disclosure of how a Trust and founder disagreement is resolved, and whether the other labs that call for pacing publish their own control structures. A lab's safety promise is only as strong as who can overrule it.